CareDx (CDNA) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.70
- Estimate
- $0.26
- Surprise
- +174.5%
- Revenue (period 2026-09-30)
- $139.4M
- Score at report (before → after)
- 6.0 → 6.0/10
Revenue source: xbrl.
How the report landed
CareDx (CDNA) beat the $0.26 estimate with adjusted EPS of $0.70 — a large 174.5% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.0/10) to Hold at 6.0/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CDNA Hold at 6.0/10.
3 of the last 4 quarters beat the estimate; this quarter's +174.5% surprise compares with a +87.1% four-quarter average.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.1 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: AlloSure/AlloMap/HeartCare transplant tests
- Analyst target reached - limited upside remaining
- Near 52-week high (2.6% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $71.52
- Stop
- $66.51
Forward estimates sit below the trailing run-rate (55.4× forward vs 34.4× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.
CDNA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $3.70B
- P/E (fwd)
- 55.4
- P/E (ttm)
- 34.4
- 52-week range
- $14.22–$73.43
- Off 52-week high
- 2.6%
- RSI (14)
- 69
- Volume vs avg
- 1.27×
- Score today
- 6.0/10